Skip to main content

Table 2 Comparison between anti-PM/Scl-75 antibody-positive versus-negative patients

From: Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients

Disease manifestation anti-PM/Scl-75-positive
(n = 29)
anti-PM/Scl-75-negative
(n = 251)
P value Sensitivity, percentagea Specificity, percentageb
mRSSc 9.0 (11.3) 7.2 (7.4) 0.017 NA NA
Digital ulcersd 19 (65.5) 93 (37.1) 0.005 17 94
Lung fibrosisd 16 (55.2) 82 (32.7) 0.023 16.3 92.9
Restrictive lung diseased 18 (62.1) 81 (32.3) 0.001 18.2 94.8
DLCO-SBc 65.7 (18.1) 73.7 (20.7) 0.091 NA NA
Mean FVCc 80.0 (14.1) 93.6 (19.2) <0.005 NA NA
PAHd 2 (6.9) 58 (23.1) 0.054 3.3 87.7
Contracturesd 23 (79.3) 149 (59.4) 0.044 13.4 94.4
CK elevationd 10 (34.5) 27 (10.8) 0.002 27 92.2
Muscle atrophyd 19 (65.5) 111 (44.2) 0.032 14.6 93.3
Colon involvementd 7(24.1) 112 (44.6) 0.046 5.9 86.3
Disease activityc 2.0 (1.2) 1.5 (1.3) 0.037 NA NA
  1. Clinical differences between antibody-positive and -negative patients were shown only when P values of below 0.1 were detected. aProbability that patients with the respective disease manifestation are anti-PM/Scl-75-positive; for example, sensitivity of anti-PM/Scl-75 (digital ulcers) = 19/(19 + 93) = 0.17. bProbability that patients without the respective disease manifestation are anti-PM/Scl-75-negative; for example, specificity of anti-PM/Scl-75 (digital ulcers) = (251 - 93)/(29 - 19 + 251 - 93) = 0.94. cValues displayed are medians (standard deviations). dValues displayed are numbers of patients (percentages). CK, creatine kinase; DLCO-SB, predicted diffusion capacity of a single breath; FVC, forced vital capacity; mRSS, modified Rodnan skin score; NA, not applicable; PAH, pulmonary arterial hypertension.